Tiamaes(SZ:300807) Xin Lang Zheng Quan·2025-06-06 03:13Group 1 - In May 2025, the number of newly registered private equity and venture capital fund managers in China dropped to 2, a decrease of 83.3% compared to April and a 60% decline year-on-year [1] - A total of 339 new private equity and venture capital funds were registered, marking a year-on-year increase of 55.5% but a month-on-month decrease of 18.7% [1] - The domestic primary equity investment market recorded 428 financing events, representing a year-on-year and month-on-month decrease of 13.6% and 18.0%, respectively, with a total disclosed financing amount of approximately 18.233 billion yuan, remaining stable compared to May 2024 but down 21.5% from March 2025 [1] Group 2 - Qiming Venture Partners managed a total capital of 9.5 billion USD (over 69 billion yuan) across 11 USD funds and 7 RMB funds, having invested in over 530 companies in technology, consumer, and healthcare sectors [2] - As of May 2025, Qiming Venture Partners registered only one fund, the Suzhou Qichen Hengyuan Equity Investment Partnership, with a registered capital of 460 million yuan, which is intended for acquiring shares in Tianmai Technology [2] - The acquisition of 26.1% of Tianmai Technology for 452 million yuan positions Qiming as the controlling shareholder, with the company’s market value at 1.732 billion yuan [2] Group 3 - Tianmai Technology, established in 2004, focuses on intelligent public transportation solutions but has faced declining performance due to reduced passenger traffic and local government subsidies [3] - Qiming Venture Partners aims to leverage its resources to help Tianmai Technology reduce costs and explore new markets to reverse its operational decline [3] - In the reported period, Qiming disclosed 4 equity investment events, showing a significant increase of 300% year-on-year and month-on-month [3] Group 4 - In May 2025, Qiming's participation in B-round projects accounted for 75% of its investments, with a notable investment in medical device company "Pam Medical" [5] - Qiming also invested in the AI sector, specifically in a company developing general-purpose robots [5] Group 5 - Haobo Pharmaceutical completed a 50 million USD B+ round financing, with funds aimed at supporting the clinical development of its innovative drug AHB-137 for chronic hepatitis B [7] - Qiming has previously invested in Haobo during its A and B rounds, totaling 11 million USD [8]